Huma raises $130 million financing to scale its digital health platform for better care and research
USA - English
News provided by
Share this article
, May 12, 2021 /PRNewswire/
Huma Therapeutics Limited today announces the completion of its latest funding round with financing of approximately $130 million. The investment will scale Huma s modular platform which can power digital hospitals at home nationally, and support the pharmaceutical and research industries to run the largest ever decentralized clinical trials. Huma s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV , Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekm
December 21, 2020
December 21, 2020 | Funding updates around the life sciences including cash for a handheld mass spec device, Series D for oncolytic immunotherapy, a new company launch in allogenic CAR-NK cells, AI-powered cell classification, a 3-D sequencing platform, and more.
$170M: Israeli ‘Digital Health First’ VC Firm
OTV (formerly Olive Tree Ventures), Israel’s ‘digital health first’ venture capital firm, today announced the closing of a fund with a total value of $170M. OTV also announced their new name and the appointment of a new Head of Asia Pacific to spearhead the fund’s expansion into the region’s market. OTV is the only venture capital fund in Israel whose primary focus is digital health, specializing in supporting their portfolio companies reach maturity, refine execution, tackle regulatory hurdles and ensure a global imprint on validated products. Over the course of the past five years, OTV has prioritized investment in digital health